LDX — Lumos Diagnostics Holdings Income Statement
0.000.00%
- AU$19.46m
- AU$23.02m
- $11.13m
- 52
- 64
- 40
- 53
Annual income statement for Lumos Diagnostics Holdings, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
C2020 June 30th | R2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 5.63 | 18.9 | 11.6 | 10.5 | 11.1 |
Cost of Revenue | |||||
Gross Profit | 2.44 | 8.6 | 4.46 | 5.97 | 7.1 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14.2 | 29.7 | 56.7 | 20.3 | 18.6 |
Operating Profit | -8.56 | -10.8 | -45.1 | -9.75 | -7.52 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -9.07 | -15 | -45.7 | -8.97 | -8.59 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.01 | -15 | -45.7 | -8.97 | -8.59 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.01 | -15 | -45.7 | -8.97 | -8.59 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.01 | -15 | -45.7 | -8.97 | -8.59 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.053 | -0.094 | -0.108 | -0.04 | -0.016 |
Dividends per Share |